Natalizumab

Real-world comparison of natalizumab exit strategies in patients with RRMS 9:25
Real-world comparison of natalizumab exit strategies in patients with RRMS
Aurora Zanghì • 22 Jun 2021
Benefits of SC natalizumab in MS 2:43
Benefits of SC natalizumab in MS
Bart Van Wijmeersch • 23 Jun 2021
Enhancing convenience and flexibility with SC natalizumab for MS 2:19
Enhancing convenience and flexibility with SC natalizumab for MS
Bart Van Wijmeersch • 23 Jun 2021
NfL to monitor treatment effects in MS 3:26
NfL to monitor treatment effects in MS
Charlotte Teunissen • 4 Jun 2021
Novel biomarkers to predict progression in MS 4:28
Novel biomarkers to predict progression in MS
Charlotte Teunissen • 4 Jun 2021
Low serum contactin-1 predicts disability progression in MS 4:27
Low serum contactin-1 predicts disability progression in MS
Charlotte Teunissen • 4 Jun 2021
Natalizumab improves mental and social health in a real-world MS cohort 3:53
Natalizumab improves mental and social health in a real-world MS cohort
Carrie Hersh • 3 May 2021
Managing pediatric MS in the current era 1:46
Managing pediatric MS in the current era
Tanuja Chitnis • 26 Apr 2021
Safely switching from natalizumab to ocrelizumab in patients with MS at risk of PML 2:14
Safely switching from natalizumab to ocrelizumab in patients with MS at risk of PML
Claire Riley • 26 Feb 2021
Determining the optimal treatment strategy in MS 4:18
Determining the optimal treatment strategy in MS
Tanuja Chitnis • 23 Feb 2021
The content of VJNeurology is intended for healthcare professionals